Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies

Published on Dec 1, 2019in Stem Cell Research & Therapy4.627
· DOI :10.1186/s13287-019-1224-y
N. C. Nadia de Cassia Noronha1
Estimated H-index: 1
(USP: University of São Paulo),
Amanda Mizukami7
Estimated H-index: 7
(USP: University of São Paulo)
+ 5 AuthorsKelen C. R. Malmegrim15
Estimated H-index: 15
(USP: University of São Paulo)
Multipotent mesenchymal stromal cells (MSC) have been widely explored for cell-based therapy of immune-mediated, inflammatory, and degenerative diseases, due to their immunosuppressive, immunomodulatory, and regenerative potentials. Preclinical studies and clinical trials have demonstrated promising therapeutic results although these have been somewhat limited. Aspects such as low in vivo MSC survival in inhospitable disease microenvironments, requirements for ex vivo cell overexpansion prior to infusions, intrinsic differences between MSC and different sources and donors, variability of culturing protocols, and potency assays to evaluate MSC products have been described as limitations in the field. In recent years, priming approaches to empower MSC have been investigated, thereby generating cellular products with improved potential for different clinical applications. Herein, we review the current priming approaches that aim to increase MSC therapeutic efficacy. Priming with cytokines and growth factors, hypoxia, pharmacological drugs, biomaterials, and different culture conditions, as well as other diverse molecules, are revised from current and future perspectives.
Figures & Tables
  • References (167)
  • Citations (4)
📖 Papers frequently viewed together
19 Citations
61 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Koichi FujisawaH-Index: 12
#2Taro TakamiH-Index: 12
Last. Isao SakaidaH-Index: 46
view all 8 authors...
4 CitationsSource
#1Zizhao Wu (SYSU: Sun Yat-sen University)H-Index: 4
#2Xianjian Qiu (SYSU: Sun Yat-sen University)H-Index: 3
Last. Dongsheng Huang (SYSU: Sun Yat-sen University)H-Index: 14
view all 12 authors...
12 CitationsSource
#1Luiza Bagno (UM: University of Miami)H-Index: 6
#2Konstantinos E. Hatzistergos (UM: University of Miami)H-Index: 20
Last. Joshua M. Hare (UM: University of Miami)H-Index: 92
view all 4 authors...
Administration of mesenchymal stem cells (MSCs) to diseased hearts improves cardiac function and reduces scar size. These effects occur via the stimulation of endogenous repair mechanisms, including regulation of immune responses, tissue perfusion, inhibition of fibrosis, and proliferation of resident cardiac cells, although rare events of transdifferentiation into cardiomyocytes and vascular components are also described in animal models. While these improvements demonstrate the potential of st...
13 CitationsSource
#1Seul-Gi Lee (Catholic University of Korea)H-Index: 2
#2Young Ae Joe (Catholic University of Korea)H-Index: 13
Abstract Mesenchymal stromal/stem cells (MSCs) have been promising source for regenerative cell therapy in ischemic diseases. To improve efficacy of MSC therapy, various priming methods have been developed, and hypoxic priming has been reported to enhance therapeutic efficacy of MSCs by increasing secretion level of growth factors and cytokines. Recently, it has been reported that bone marrow MSCs primed with hypoxic condition show an increase of autophagy. Here, we addressed whether proangiogen...
4 CitationsSource
#1Katsuyuki TakedaH-Index: 45
#2Fangkun NingH-Index: 2
Last. Erwin W. GelfandH-Index: 90
view all 11 authors...
2 CitationsSource
#1Bo Gao (SYSU: Sun Yat-sen University)H-Index: 4
#2Wenjie Gao (Xi'an Jiaotong University)H-Index: 6
Last. Dongsheng Huang (SYSU: Sun Yat-sen University)H-Index: 14
view all 15 authors...
Background Osteoarthritis (OA) is a widespread arthritic disease and a primary cause of disability. Increasing evidence suggests that inflammation has a pivotal part in its pathogenesis. Interleukin-1β (IL-1β) is a primary mediator of local inflammatory processes in OA. Current therapies for OA mainly focus on the symptoms of the advanced stage of the disease. The possible utilization of bone marrow mesenchymal stem cells (BMSCs) to regenerate cartilage is an appealing method, but in the case of...
3 CitationsSource
#1Rui Xu (SDU: Shandong University)H-Index: 1
#2Wenbin Chen (SDU: Shandong University)H-Index: 1
Last. Wei Lu (SDU: Shandong University)H-Index: 1
view all 7 authors...
Abstract Bone-Marrow Stromal Cells (BMSCs)-derived vascular endothelial cells (VECs) is regarded as an important therapeutic strategy for spinal cord injury, disc degeneration, cerebral ischemic disease and diabetes. The change in DNA methylation level is essential for stem cell differentiation. However, the DNA methylation related mechanisms underlying the endothelial differentiation of BMSCs are not well understood. In this study, DNA methyltransferase inhibitor, 5-aza-2′-deoxycytidine (5-aza-...
2 CitationsSource
#1Amanda Mizukami (USP: University of São Paulo)H-Index: 7
#2Kamilla Swiech (USP: University of São Paulo)H-Index: 12
Over the last decades, mesenchymal stromal cells (MSC) have been the focus of intense research by academia and industry due to their unique features. MSC can be easily isolated and expanded through in vitro culture by taking full advantage of their self-renewing capacity. In addition, MSC exert immunomodulatory effects and can be differentiated into various lineages, which makes them highly attractive for clinical applications in cell-based therapies. In this review, we attempt to provide a brie...
13 CitationsSource
#1Xiao Xia Cong (ZJU: Zhejiang University)H-Index: 2
#2Xi Sheng Rao (ZJU: Zhejiang University)H-Index: 2
Last. Yi Ting Zhou (ZJU: Zhejiang University)H-Index: 12
view all 18 authors...
Tendon repair is a clinical challenge because of the limited understanding on tenogenesis. The synthesis of type I collagen (Collagen I) and other extracellular matrix are essential for tendon differentiation and homeostasis. Current studies on tenogenesis focused mostly on the tenogenic transcriptional factors while the signaling controlling tenogenesis on translational level remains largely unknown. Here, we showed that mechanistic target of rapamycin (mTOR) signaling was activated by protenog...
7 CitationsSource
#1Xiaoyu Sun (Sichuan University)H-Index: 3
#2Wen Su (Sichuan University)H-Index: 5
Last. Xudong Li (Sichuan University)H-Index: 6
view all 6 authors...
Collagen (COL), collagen/hydroxyapatite (COL/HA), HA and biphasic calcium phosphate were prepared as representative bone grafting materials with composition analogous to bone, and their structural characteristics were analyzed. The rat bone mesenchymal stem cells (BMSCs) were further seeded onto four groups of materials, and BMSCs grown in basic medium and standard osteogenic medium were set as controls of a reference model to show the basic and osteogenic behavior of cells without the intervent...
5 CitationsSource
Cited By4
#1Zhenkun Wang (HMU: Harbin Medical University)
#2X. L. Liu (HMU: Harbin Medical University)H-Index: 1
Last. Song Guo Zheng (OSU: Ohio State University)H-Index: 1
view all 6 authors...
Autoimmune diseases (ADs) are a serious hazard to human health and well-being. As an alternative therapeutic approach, cell therapy, in which cellular material is injected or implanted into a patient, has the potential to overcome the limitations of traditional drug treatment and to alleviate the symptoms of many refractory diseases. The use of cell therapy has led to the development of new techniques and significantly contributed to the promise of inducing immune tolerance and restoring immunol...
#1Sabine Galland (UNIL: University of Lausanne)H-Index: 2
#2Patricia Martin (UNIL: University of Lausanne)H-Index: 6
Last. Ivan Stamenkovic (UNIL: University of Lausanne)H-Index: 27
view all 5 authors...
Abstract Solid tumor growth triggers a dynamic host response, which recapitulates wound healing and defines the tumor microenvironment (TME). In addition to the action of the tumor cells themselves, the TMEis maintained by a myriad of immune and stromal cell-derived soluble mediators and extracellular matrix components whose combined action supports tumor progression. However, therapeutic targeting of the TME has proven challenging because of incomplete understanding of the tumor-host crosstalk ...
BACKGROUND: Mesenchymal stromal cell (MSC)-enriched products showed positive clinical outcomes in regenerative medicine, where tissue restoration and inflammation control are needed. GMP-expanded MSCs displayed an even higher potential due to exclusive secretion of therapeutic factors, both free and conveyed within extracellular vesicles (EVs), collectively termed secretome. Moreover, priming with biochemical cues may influence the portfolio and biological activities of MSC-derived factors. For ...
Regenerative medicine has recently improved the principal therapies in several medical fields. In the past ten years, the continuous search for novel approaches to treat the most common dental pathologies has developed a new branch called regenerative dentistry. The main research fields of translational dentistry involve biomimetic materials, orally derived stem cells, and tissue engineering to populate scaffolds with autologous stem cells and bioactive growth factors. The scientific literature ...
#1Amandda Évelin Silva-Carvalho (UnB: University of Brasília)H-Index: 1
#2Leane Perim Rodrigues (UCB: Universidade Católica de Brasília)
Last. Felipe Saldanha-Araujo (UnB: University of Brasília)H-Index: 8
view all 10 authors...
BACKGROUND: Mesenchymal stem cell (MSC) therapy is an important alternative for GVHD treatment, but a third of patients fail to respond to such therapy. Therefore, strategies to enhance the immunosuppressive potential of MSCs constitute an active area of investigation. Here, we proposed an innovative priming strategy based on the plasma obtained from GVHD patients and tested whether this approach could enhance the immunosuppressive capacity of MSCs. METHODS: We obtained the plasma from healthy a...
#1Francisco Moreira (IST: Instituto Superior Técnico)H-Index: 2
#1Francisco Moreira (University of Lisbon)H-Index: 34
Last. Kamilla Swiech (USP: University of São Paulo)H-Index: 12
view all 7 authors...
Mesenchymal stem/stromal cells (MSC) are promising candidates for cell-based therapies and for the promotion of tissue repair, hence the increase of clinical trials in a worldwide scale. In particular, adipose tissue-derived stem/stromal cells (AT MSC) present easy accessibility and a rather straightforward process of isolation, providing a clear advantage over other sources. The high demand of cell doses (millions of cells/kg), needed for infusion in clinical settings, requires a scalable and e...
Last. Oksana Kehoe (Keele University)H-Index: 6
view all 5 authors...
Umbilical cord mesenchymal stromal cells (UCMSCs) have shown an ability to modulate the immune system through the secretion of paracrine mediators, such as extracellular vesicles (EVs). However, the culture conditions that UCMSCs are grown in can alter their secretome and thereby affect their immunomodulatory potential. UCMSCs are commonly cultured at 21% O2 in vitro, but recent research is exploring their growth at lower oxygen conditions to emulate circulating oxygen levels in vivo. Additional...
#2Pietro RomeleH-Index: 4
Last. Ornella ParoliniH-Index: 40
view all 8 authors...
BACKGROUND: Equine amniotic mesenchymal stromal cells (AMSCs) and their conditioned medium (CM) were evaluated for their ability to inhibit in vitro proliferation of peripheral blood mononuclear cells (PBMCs) with and without priming. Additionally, AMSC immunogenicity was assessed by expression of MHCI and MHCII and their ability to counteract the in vitro inflammatory process. METHODS: Horse PBMC proliferation was induced with phytohemagglutinin. AMSC priming was performed with 10 ng/ml of TNF-...
#1Bong-Woo Park (Catholic University of Korea)
#2Soo-Hyun Jung (Catholic University of Korea)
Last. Hey-Yon KimH-Index: 1
view all 15 authors...
The clinical use of human bone marrow–derived mesenchymal stem cells (BM-MSCs) has been hampered by their poor performance after transplantation into failing hearts. Here, to improve the therapeutic potential of BM-MSCs, we developed a strategy termed in vivo priming in which BM-MSCs are primed in vivo in myocardial infarction (MI)–induced hearts through genetically engineered hepatocyte growth factor–expressing MSCs (HGF-eMSCs) that are encapsulated within an epicardially implanted 3D cardiac p...
Mesenchymal stromal cells (MSCs) are among of the most studied cell type for cellular therapy thanks to the ease of isolation, cultivation, and the high ex vivo expansion potential. In 2018, the European Medicines Agency finally granted the first marketing authorization for an MSC product. Despite the numerous promising results in preclinical studies, translation into routine practice still lags behind: therapeutic benefits of MSCs are not as satisfactory in clinical trial settings as they appea...